Farxiga vs Lantus: Side-Effect Profile Head-to-Head

How These Drugs Work Differently

Farxiga blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, forcing the kidneys to excrete roughly 70 g of glucose per day through urine 1. Lantus supplies exogenous basal insulin as a once-daily injection that forms microprecipitates under the skin, releasing insulin glargine over approximately 24 hours.

This mechanistic split explains nearly every safety difference between the two medications. Because Farxiga works independently of insulin secretion, it rarely causes hypoglycemia on its own. Because Lantus directly raises circulating insulin levels, hypoglycemia is dose-dependent and always a concern. The glucose that Farxiga dumps into urine creates a warm, sugar-rich environment in the urogenital tract. That is the price of an insulin-independent glucose-lowering strategy: infections go up while blood sugar crashes go down.

Neither drug acts on the same receptor, the same organ system, or the same physiological pathway. Comparing their side effects is less like comparing two sedans and more like comparing a sedan to a boat. Both get you from point A to point B, but the hazards along the way look nothing alike.

Hypoglycemia: The Defining Safety Gap

Hypoglycemia is the most clinically significant difference between these medications. Lantus causes it. Farxiga, used alone, almost never does.

In the ORIGIN trial (N=12,537), patients randomized to insulin glargine experienced confirmed severe hypoglycemia at a rate of 1.00 event per 100 person-years, compared with 0.31 in the standard-care group 2. The rate of non-severe symptomatic episodes was substantially higher, with participants on glargine reporting symptomatic hypoglycemia at more than double the rate of those on standard care. Over the 6.2-year median follow-up, roughly 42% of glargine-treated participants experienced at least one episode of confirmed hypoglycemia.

Farxiga monotherapy studies report severe hypoglycemia in fewer than 1% of patients across 24-week trials 3. The SGLT2 mechanism cannot push glucose below the renal threshold for reabsorption, which provides a built-in floor. Hypoglycemia risk with dapagliflozin rises only when it is combined with sulfonylureas or insulin, a pattern confirmed in pooled analyses of over 9,000 patients 4.

For patients who live alone, drive commercially, or have hypoglycemia unawareness, this gap is not academic. It is the primary reason many clinicians now reach for an SGLT2 inhibitor before basal insulin in type 2 diabetes algorithms, as reflected in the 2022 ADA/EASD consensus report.

Genital and Urinary Tract Infections

Farxiga's renal glucose excretion creates a measurable infection risk that Lantus does not share.

Genital mycotic infections (vulvovaginal candidiasis in women, balanitis in men) occurred in 5.7% of women and 2.8% of men taking dapagliflozin 10 mg, versus 0.9% and 0.3% on placebo, according to pooled phase III data submitted to the FDA 5. Most infections were mild to moderate and responded to a single course of topical antifungal treatment. Recurrence rates remained below 2%. Urinary tract infections showed a smaller but real increase: approximately 5.7% with dapagliflozin versus 3.7% with placebo across the same pooled dataset.

Lantus does not alter urinary glucose concentration and carries no signal for increased genitourinary infections in any major trial.

A practical way to frame this for patients: Farxiga trades hypoglycemia risk for infection risk. The infections are treatable, predictable, and often preventable with basic hygiene counseling. Severe hypoglycemia can result in seizures, motor vehicle accidents, and death.

Weight: Loss vs Gain

Patients notice weight changes. These are not trivial side effects in a disease driven by metabolic excess.

Dapagliflozin 10 mg produced a mean weight reduction of 2.08 kg at 24 weeks versus placebo in a pooled analysis of 2,098 patients 6. Weight loss was durable over 102 weeks of follow-up in extension studies, with the full 10 mg dose group maintaining approximately 2.5 to 3.0 kg of net loss versus placebo. The mechanism is straightforward caloric wasting: excreting 70 g of glucose daily removes roughly 280 kcal.

In ORIGIN, insulin glargine led to a mean weight gain of 1.6 kg over the median 6.2-year follow-up, compared with standard care 2. Some patients in the trial gained considerably more. Insulin-driven weight gain compounds insulin resistance, creating a feedback loop that may require progressive dose escalation.

The 2022 ADA Standards of Care identify weight effect as a factor in diabetes medication selection, specifically recommending agents with weight-loss properties for patients with overweight or obesity 7. This preference gives Farxiga a structural advantage over Lantus in the treatment algorithm for the majority of type 2 diabetes patients, since roughly 85-90% have BMI above 25.

Cardiovascular and Renal Outcomes

The cardiovascular safety data between these two drugs are not symmetrical. Farxiga has demonstrated benefit. Lantus has demonstrated neutrality.

DAPA-HF (N=4,744) randomized patients with heart failure with reduced ejection fraction (HFrEF), with and without diabetes, to dapagliflozin 10 mg or placebo. The primary composite endpoint of worsening heart failure or cardiovascular death occurred in 16.3% of the dapagliflozin group versus 21.2% of placebo (HR 0.74 to 95% CI 0.65-0.85, P<0.001) 8. The number needed to treat was 21 over a median 18.2-month follow-up. This result led to FDA approval of Farxiga for HFrEF regardless of diabetes status.

ORIGIN (N=12,537) tested whether early introduction of basal insulin glargine in people with dysglycemia or early type 2 diabetes would reduce cardiovascular events. It did not. The hazard ratio for the primary composite of CV death, nonfatal MI, or nonfatal stroke was 1.02 (95% CI 0.94-1.11) 2. ORIGIN did settle a long-running concern about whether exogenous insulin promotes atherosclerosis. The answer: it does not appear to, at least not through the glargine formulation.

Dapagliflozin also showed renal protection in DAPA-CKD (N=4,304), reducing the composite of sustained eGFR decline, end-stage kidney disease, or renal death by 39% (HR 0.61 to 95% CI 0.51-0.72, P<0.001) 9. Insulin glargine has no comparable renal outcome data.

For patients with established heart failure or chronic kidney disease, this disparity makes the choice simple. Farxiga offers organ protection that Lantus cannot match.

Diabetic Ketoacidosis: A Rare but Serious Farxiga Risk

Euglycemic diabetic ketoacidosis (euDKA) is a hazard unique to SGLT2 inhibitors. Because Farxiga lowers glucose while shifting metabolism toward fatty acid oxidation, ketone production can rise even when blood sugar appears normal or only mildly elevated. The FDA added a warning to all SGLT2 inhibitor labels in 2015 10.

Reported rates of DKA with dapagliflozin range from 0.1% to 0.2% in randomized trials. The risk increases during surgery, prolonged fasting, acute illness, or significant carbohydrate restriction. The practical instruction is clear: hold Farxiga at least 3 days before elective surgery and resume only after the patient is eating and drinking normally.

Lantus does not cause euDKA. If anything, adequate basal insulin coverage prevents DKA in insulin-deficient patients.

Volume Depletion and Blood Pressure Effects

Farxiga has a mild osmotic diuretic effect. Glycosuria pulls water into the tubular lumen, producing a net fluid loss of approximately 375 mL per day in early treatment 11. This effect reduces systolic blood pressure by 3-5 mmHg on average, which is beneficial for most patients with type 2 diabetes but can cause orthostatic hypotension, dizziness, or dehydration in elderly patients on loop diuretics.

In pooled clinical trial data, volume depletion events (hypotension, dehydration, syncope) occurred in 1.1% of dapagliflozin-treated patients versus 0.7% on placebo 5. Risk factors include age over 75, concurrent diuretic use, and eGFR below 45 mL/min/1.73m².

Lantus does not cause osmotic diuresis. It does not lower blood pressure. It does not increase dehydration risk. For a frail, elderly patient already taking furosemide and lisinopril, this distinction may steer the prescribing decision.

Injection-Site Reactions and Administration Burden

Lantus requires subcutaneous injection. Injection-site reactions (lipodystrophy, nodules, pruritus) affect roughly 2-4% of patients over time 12. Lipohypertrophy at injection sites can alter insulin absorption kinetics and lead to erratic glycemic control if patients do not rotate sites.

Farxiga is a once-daily 10 mg oral tablet. There are no injection-site reactions. Reported GI side effects are uncommon and mild: nausea in approximately 2.5% versus 2.2% on placebo, and diarrhea at similar rates.

For patients with needle phobia, dexterity limitations, or those already managing multiple daily injections (pre-mixed insulin, GLP-1 agonists), the oral route of administration is a meaningful quality-of-life advantage.

Cancer Signal: Addressed and Resolved

Early dapagliflozin trials raised a numerical signal for bladder cancer. The FDA reviewed this extensively and determined in 2017 that there was no causal association, based on updated data from a large post-marketing study and the expected latency period for solid tumors 5. The bladder cancer warning was removed from the Farxiga label.

ORIGIN evaluated whether insulin glargine increases cancer risk, given insulin's known mitogenic properties. Over 6.2 years, there was no difference in cancer incidence between glargine and standard care (HR 1.00 to 95% CI 0.88-1.13) 2. This finding was reassuring and consistent with the ORIGIN investigators' pre-specified analysis.

Neither drug, based on available long-term data, carries a confirmed cancer risk.

Fournier Gangrene: The FDA's Post-Market Warning

In 2018, the FDA issued a safety communication about necrotizing fasciitis of the perineum (Fournier gangrene) associated with SGLT2 inhibitors, including dapagliflozin 10. Between March 2013 and January 2019, the FDA identified 55 cases across all SGLT2 inhibitors, representing an extremely rare but life-threatening complication. Patients should be counseled to seek immediate medical attention for perineal pain, tenderness, erythema, or swelling.

Lantus has no association with Fournier gangrene or soft-tissue infections of any kind.

Who Should Choose Which Drug

The side-effect profiles of these two medications map onto different patient risk factors. A patient with heart failure, obesity, and intact renal function benefits from Farxiga's cardiovascular protection and weight loss, while accepting a small risk of genital infection and euDKA. A patient with type 1 diabetes features, very low C-peptide, or recurrent urinary infections may be better served by basal insulin.

The American Diabetes Association's 2024 Standards of Care position SGLT2 inhibitors ahead of basal insulin in the treatment algorithm for most patients with type 2 diabetes, specifically recommending them when heart failure or CKD is present, independent of A1C 7. Insulin remains the appropriate choice when endogenous insulin production is severely impaired or when glucose toxicity requires rapid correction.

Clinicians should check baseline eGFR before starting dapagliflozin (initiation is not recommended below 25 mL/min/1.73m² for glycemic benefit), screen for recurrent fungal infections, and counsel patients on perioperative holding protocols.